XML 103 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative and license agreements          
AbbVie's receivable from Janssen $ 12,769   $ 12,769   $ 10,919
AbbVie's payable to Janssen 33,619   33,619   31,945
Janssen Biotech Inc. | Collaborative arrangement          
Collaborative and license agreements          
Milestone payments 200   $ 200    
Share of collaboration development costs responsible by Janssen (as a percent)     60.00%    
Share of collaboration development costs responsible by the entity (as a percent)     40.00%    
Global - AbbVie's share of other costs (included in respective line items) 24 $ 38 $ 74 $ 120  
AbbVie's receivable from Janssen 221   221   237
AbbVie's payable to Janssen 217   217   $ 282
Janssen Biotech Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 235 282 735 849  
Janssen Biotech Inc. | Collaborative arrangement | International          
Collaborative and license agreements          
International - AbbVie's share of profits (included in net revenues) 199 210 619 676  
Genentech, Inc. | Collaborative arrangement          
Collaborative and license agreements          
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 286 263 790 733  
AbbVie's share of development costs (included in R&D) 15 21 47 63  
Genentech, Inc. | Collaborative arrangement | United States          
Collaborative and license agreements          
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 13 $ 10 $ 26 $ 25